Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Philippe Jablonski

Matthias Heinrich Nettekoven

Hasane Ratni

Henner Knust

Claus Riemer

Caterina Bissantz

Anja Limberg

Xihan Wu

Kenichi Kawasaki

Angelique Patiny-Adam

Heinz Stadler

Torsten Hoffmann

Andreas Koblet

Angélique Patiny-Adam

The present invention relates to a compound of formula I wherein R, R, R, Ar, and n are as defined hereinor to a pharmaceutically active acid addition salt. Compounds of formula I show a high affinity simultaneously to both the NK1 and the NK3 receptors (dual NK1/NK3 receptor antagonists), useful in the treatment of schizophrenia.

Pyrrazolopyridine compounds as dual NK1/NK3 receptor antagonists

The present invention relates to compounds of formula I wherein R, R, R, Ar and n are as defined herein and pharmaceutically active salts, racemic mixtures, enantiomers, optical isomers or tautomeric forms thereof. The compounds can be used for the treatment of depression, anxiety or schizophrenia.

Pyrrolidine derivatives as NK2 receptor antagonists

The present invention relates to a compounds of formula I wherein R, R, Ar, Ar, R', R&#x2033;, m, n, and o are defined in the specification or to a pharmaceutically active salt, racemic mixture, enantiomer, optical isomer or to tautomeric form thereof. The present compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidines as NK3 receptor antagonists

The present invention relates to a compound of formula I wherein

Pyrrolidine derivatives as NK-3 receptor antagonists

The present invention relates to compounds of formula I wherein R, R, R, R', Ar, m, n, and o are as defined herein. The invention also relates to pharmaceutical compositions containing compounds of formula I and methods for the manufacture of such compounds and compositions. Compounds of the invention are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Pyrrolidine ether derivatives as NK3 receptor antagonists

N-benzyl pyrrolidine derivatives

The invention relates to a compound of formula I wherein

Pyrrolidine aryl-ether as NK-3 receptor antagonists

The invention relates to pyrrolidine derivatives of formula wherein

Pyrrolidine derivatives as dual NK1/NK3 receptor antagonists

The invention relates to a compound of general formula wherein are as defined herein or to a pharmaceutically active salt thereof, including all stereoisomeric forms, individual diastereoisomers and enantiomers of the compound of formula (I) as well as racemic and non-racemic mixtures thereof. The compounds are high potential NK-3 receptor antagonists for the treatment of depression, pain, psychosis, Parkinson's disease, schizophrenia, anxiety and attention deficit hyperactivity disorder (ADHD).

Growing community of inventors

Steinbrunn-le-Haut, France

Philippe Jablonski